AngioDynamics ( (ANGO) ) has shared an announcement.
AngioDynamics announced a promising start to fiscal year 2025 with a slight increase in overall net sales and significant growth in its Med Tech segment, driven by Auryon and AlphaVac products. The company reported a GAAP net loss but a reduced adjusted net loss per share compared to the previous year and has provided an optimistic outlook with expected growth in both Med Tech and Med Device net sales. Despite the challenges of inflationary pressures and manufacturing transitions, AngioDynamics is focused on executing its growth strategy and advancing its innovative product portfolio, including recent FDA submissions and European approvals.
See more data about ANGO stock on TipRanks’ Stock Analysis page.
